Table 3.
Association between high expression of integrin α4 and the clinicopathological parameters
| Localization | Primary tumor | Omentum | Peritoneum | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| High expression | Yes | No | p value | Yes | No | p value | Yes | No | p value | |
| Age (median; range) | 60.1 (31.7–76.5) | 65.5 (45.4–78.3) | 0.180 | 59.1 (31.7–76.5) | 69.8 (53.1–78.3) | 0.007 | 61.5 (31.7–76.5) | 67.5 (48.6–78.3) | 0.047 | |
| Tumor size (median; range) | 5.0 (1.5–14.0) | 5.5 (2.0–12.0) | 0.950 | 4.5 (1.5–14.0) | 5.5 (2.0–12.0) | 0.778 | 5.0 (1.5–11.0) | 5.0 (2.0–14.0) | 0.286 | |
| FIGO | III | 14 (45.2%) | 17 (54.8%) | 0.133 | 13 (46.4%) | 15 (53.6%) | 0.252 | 13 (44.8%) | 16 (55.2%) | 0.232 |
| IV | 7 (77.8%) | 2 (22.2%) | 6 (66.7%) | 3 (33.3%) | 6 (75.0%) | 2 (25.0%) | ||||
| Nodal status | N0 | 5 (50.0%) | 5 (50.0%) | 0.685 | 4 (50.0%) | 4 (50.0%) | 0.608 | 3 (33.3%) | 6 (66.7%) | 0.387 |
| N1 | 8 (61.5%) | 5 (38.5%) | 6 (46.2%) | 7 (53.8%) | 7 (58.3%) | 5 (41.7%) | ||||
| ER | Positive | 19 (52.8%) | 17 (47.2%) | 1.000 | 17 (51.5%) | 16 (48.5%) | 0.677 | 18 (54.5%) | 15 (45.5%) | 0.340 |
| Negative | 2 (50.0%) | 2 (50.0%) | 2 (50.0%) | 2 (50.0%) | 1 (25.0%) | 3 (75.0%) | ||||
| PR | Positive | 6 (35.3%) | 11 (64.7%) | 0.109 | 6 (37.5%) | 10 (62.5%) | 0.127 | 10 (62.5%) | 6 (37.5%) | 0.325 |
| Negative | 15 (65.2%) | 8 (34.8%) | 13 (61.9%) | 8 (38.1%) | 9 (42.9%) | 12 (57.1%) | ||||
| Ki-67 (median; range) | 50.0 (2.0–80.0) | 50.0 (15.0–80.0) | 0.521 | 40.0 (5.0–80.0) | 50.0 (2.0–80.0) | 0.689 | 50.0 (2.0–80.0) | 50.0 (5.0–80.0) | 0.797 | |
| p53 | Positive | 18 (50.0%) | 18 (50.0%) | 1.000 | 16 (48.5%) | 17 (51.5%) | 0.500 | 18 (52.9%) | 16 (47.1%) | 1.000 |
| Negative | 2 (66.7%) | 1 (33.3%) | 2 (66.7%) | 1 (33.3%) | 1 (50.0%) | 1 (50.0%) | ||||
| Residual tumor | Yes | 14 (56.0%) | 11 (44.0%) | 0.745 | 13 (56.5%) | 10 (43.5%) | 0.320 | 14 (60.9%) | 9 (39.1%) | 0.184 |
| No | 7 (46.7%) | 8 (53.3%) | 6 (42.9%) | 8 (57.1%) | 5 (35.7%) | 9 (64.3%) | ||||
| Recurrence status | Recurrence | 20 (54.1%) | 17 (45.9%) | 0.596 | 18 (52.9%) | 16 (47.1%) | 0.479 | 19 (55.9%) | 15 (44.1%) | 0.105 |
| Without recurrence | 1 (33.3%) | 2 (66.7%) | 1 (33.3%) | 2 (66.7%) | 0 (0.0%) | 3 (100.0%) | ||||
| Living status | Living | 2 (50.0%) | 2 (50.0%) | 1.000 | 1 (25.0%) | 3 (75.0%) | 0.281 | 0 (0.0%) | 4 (100.0%) | 0.046 |
| Dead | 19 (52.8%) | 17 (47.2%) | 18 (54.5%) | 15 (45.5%) | 19 (57.6%) | 14 (42.4%) | ||||
ER estrogen receptor, FIGO Fédération Internationale de Gynécologie et d’Obstétrique, PR progesterone receptor